Alk-Abelló A/S
🇩🇰Denmark
A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine
Phase 3
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- Drug: Grazax + AeriusDrug: Grazax + placebo
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 46
- Registration Number
- NCT01740284
- Locations
- 🇩🇪
Zentrum für Rhinologie und Allergologie, Wiesbaden, Germany
Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis
Phase 3
Completed
- Conditions
- Allergic RhinitisGrass Allergy
- Interventions
- Device: Electronic compliance device (Memozax®)
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 261
- Registration Number
- NCT01728285
- Locations
- 🇮🇹
Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy
A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy
Phase 2
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- Biological: SLITone ULTRA HDM immunotherapy
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 219
- Registration Number
- NCT01728298
- Locations
- 🇫🇷
Proffesor Alain Didier, Toulouse, France
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, PerennialRhinitis, Allergic, Nonseasonal
- Interventions
- Biological: Placebo tabletsBiological: MK-8237 tablets
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 1482
- Registration Number
- NCT01700192
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
Phase 1
Completed
- Conditions
- Rhinitis, Allergic, PerennialRhinitis, Allergic, Nonseasonal
- Interventions
- Biological: PlaceboBiological: MK-8237 12 DUBiological: MK-8237 6 DU
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 195
- Registration Number
- NCT01678807
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
Phase 2
Completed
- Conditions
- Birch Pollen Allergy
- Interventions
- Biological: ALK tree AIT PlaceboBiological: ALK tree AIT 0.5 DUBiological: ALK tree AIT 1 DUBiological: ALK tree AIT 4 DUBiological: ALK tree AIT 2 DUBiological: ALK tree AIT 7 DUBiological: ALK tree AIT 12 DU
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 637
- Registration Number
- NCT01675791
- Locations
- 🇳🇱
Slotervaart Ziekenhuis, Amsterdam, Netherlands
🇫🇮Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, HUS, Finland
An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy
Phase 2
Completed
- Conditions
- Allergic Rhinitis Due to Olea Europaea Pollen
- Interventions
- Biological: AVANZ olea
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 93
- Registration Number
- NCT01674595
- Locations
- 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, PerennialRhinitis, Allergic, Nonseasonal
- Interventions
- Drug: PlaceboDrug: MK-8237 6 DUDrug: MK-8237 12 DU
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 124
- Registration Number
- NCT01644617
Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis
Phase 3
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- Biological: PlaceboBiological: Pangramin SLIT HDM mix.
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 617
- Registration Number
- NCT01603056
- Locations
- 🇨🇳
No.2, Chongwenmennei Street, Dongcheng District, Beijing, Beijing, China
An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy
Phase 2
Completed
- Conditions
- Allergic Rhinitis Due to Dust Mite
- Interventions
- Biological: AVANZ MITE
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 102
- Registration Number
- NCT01568190
- Locations
- 🇪🇸
Hospital Virgen Del Camino, Pamplona, Navarra, Spain
© Copyright 2025. All Rights Reserved by MedPath